Slingshot members are tracking this event:
Bristol-Myers Squibb (BMY) Releases Phase 3 ONO-4538-12 Results Evaluating Opdivo in Patients with Unresectable Advanced or Recurrent Gastric Cancer Resistant to Standard Therapy
Slingshot Insights Explained
Nov 10, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Ono-4538-12, Opdivo, Unresectable Advanced, Recurrent, Gastric Cancer, Resistant To Standard Therapy